Compliance Risk Management Using a Top-Down Validation Approach - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Compliance Risk Management Using a Top-Down Validation Approach
Patient safety must be the primary concern of any validation effort. The author explains how a risk-based approach to validation and compliance follows naturally from this premise.


Pharmaceutical Technology


An example product applying the top-down approach


Figure 2
A sterile dry powder is filled into vials without excipients for later reconstitution with a sterile diluent (see Figure 2). The API is gamma-irradiated in bulk before the aseptic fill. The validation effort must support the methods and practices that ensure the product's critical quality attributes.

In this example (and most others), it should be immediately evident that the various quality concerns will overlap to some extent. The critical quality attributes for this product (excluding the need for a sterile diluent, which should undergo a separate assessment) are:

  • Safety—sterility, endotoxin control, foreign matter, container-closure integrity, residual solvent
  • Purity—impurities, foreign matter, lack of cross-contamination
  • Efficacy—particle size, crystal morphology, weight control, shipping studies
  • Identity—chemical structure, labeling
  • Strength—potency, stability.

Each of these primary considerations must be defined to identify the individual qualification or validation activities required to support the quality attribute in total.

Product safety requires many studies, including:

  • Aseptic filling capability
  • Sterilization of bulk powder
  • Sterilization or depyrogenation of glass containers and rubber closures
  • Sterilization of product-contact equipment
  • Sterilization of utensils
  • Filling-isolator decontamination
  • Environmental monitoring of the isolator environment
  • Water for injection systems at API, and fill–finish facility (i.e., endotoxin control)
  • Cleaning of API equipment
  • Cleaning of fill–finish equipment
  • Cleaning of empty bulk containers
  • Cleaning of container or closure
  • Bulk-container integrity
  • Final product container-closure integrity
  • Shipping studies
  • Validation of API drying.

Product purity requires attention to:

  • Impurity profiles
  • API process validation
  • API equipment cleaning
  • Foreign-matter removal
  • Absence of cross-contamination from prior products
  • Cleaning validation for API
  • Cleaning validation for fill–finish equipment
  • Bulk-container preparation
  • Container preparation
  • Stopper washing
  • Vial washing.

Efficacy mandates attention to:

  • Particle size (i.e., crystallization process)
  • Crystal morphology
  • API process validation
  • Suitability with filling equipment
  • Weight control
  • Filling equipment qualification
  • Shipping studies
  • Effect of pressure, temperature, and relative humidity
  • Bulk-powder stability (pre and poststerilization)
  • Filled-container stability.


ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters
Subscribe:Check the box next to each newsletter you wish to subscribe for:
| Weekly
| Monthly
| Monthly | Weekly
 Name:
 E-mail:

Survey
At this month's AAPS Annual Meeting & Exposition, several graduate students were awarded as young innovators. What are your thoughts on innovation and the next generation?
We need more young innovators and more students enrolling in pharma science programs
Our industry has just the right mix of young and old to keep innovation going
Age is irrelevant when it comes to innovation
We need more young innovators and more students enrolling in pharma science programs
25%
Our industry has just the right mix of young and old to keep innovation going
16%
Age is irrelevant when it comes to innovation
59%
View Results
Jim MillerOutsourcing OutlookJim Miller Facing Reality
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advancing Chiral Chemistry in API Synthesis
Faiz kermaniSpotlightFaiz Kermani Demographic time bomb
Rx-360 Takes on Europe, Talks to PharmTech in Podcast Series
Sanctions, Not Barcodes
Vaccines Finding Their Way in Novel Applications
Genzyme’s Friday the 13th
DTCA: Beneficial or Harmful?
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here